Clinical Research Directory
Browse clinical research sites, groups, and studies.
Aleniglipron Phase 2 in Type 2 Diabetes Mellitus
Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Summary
The purpose of this study is to assess the safety and tolerability of aleniglipron at doses up to 240 mg once daily (QD) in participants with T2DM who are living with obesity (body mass index \[BMI\] ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2).
Official title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Study of the Safety and Tolerability of Aleniglipron in Adult Participants With Type 2 Diabetes Mellitus Living With Obesity or Overweight
Key Details
Gender
All
Age Range
18 Years - 79 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2025-12-01
Completion Date
2026-11
Last Updated
2026-02-10
Healthy Volunteers
No
Interventions
Aleniglipron
Drug aleniglipron administered orally
Placebo
Drug placebo administered orally
Locations (17)
Research Site
Anniston, Alabama, United States
Research Site
Lake Forest, California, United States
Research Site
Lomita, California, United States
Research Site
Hazelwood, Missouri, United States
Research Site
Columbus, Ohio, United States
Research Site
Moncks Corner, South Carolina, United States
Research Site
Chattanooga, Tennessee, United States
Research Site
Knoxville, Tennessee, United States
Research Site
Austin, Texas, United States
Research Site
Austin, Texas, United States
Research Site
DeSoto, Texas, United States
Research Site
Houston, Texas, United States
Research Site
Mesquite, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Tomball, Texas, United States